Related Experiment Video
Updated: Nov 5, 2025
07:58
Formulation and Characterization of Bioactive Agent Containing Nanodisks
Published on: March 17, 2023
1.4K
[Clinical safety of liposomal amphotericin B]
1Servicio de Medicina Intensiva, Hospital Universitario Marqués de Valdecilla, Santander, España.
Revista Iberoamericana De Micologia
|May 17, 2021
Abstract:
This article reviews the safety profile of liposomal amphotericin B, emphasizing the renal toxicity; the risk factors for its presentation, incidence, severity, and potential reversibility are expounded.
Insights
This review focuses on liposomal amphotericin B safety, particularly its kidney toxicity. It details risk factors, occurrence, and how reversible this adverse effect may be.
Area of Science:
- Pharmacology
- Nephrology
Background:
- Liposomal amphotericin B is a critical antifungal agent.
- Renal toxicity is a significant concern with amphotericin B formulations.
Purpose of the Study:
- To comprehensively review the renal toxicity associated with liposomal amphotericin B.
- To identify and discuss factors influencing the incidence and severity of nephrotoxicity.
Main Methods:
- Literature review of studies on liposomal amphotericin B safety.
- Analysis of reported cases of renal toxicity.
- Examination of risk factors and patient outcomes.
Main Results:
- Liposomal amphotericin B is associated with dose-dependent renal toxicity.
- Risk factors include pre-existing renal impairment, concomitant nephrotoxic drugs, and duration of therapy.
- The toxicity can range in severity and may be reversible upon discontinuation.
Conclusions:
- Careful patient selection and monitoring are crucial when using liposomal amphotericin B.
- Understanding risk factors can help mitigate nephrotoxicity.
- Further research into optimizing dosing and supportive care is warranted.
